Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 10/20 | 0.48 |
| ▸ | NAA50 | Q9GZZ1 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 4/20 | 0.43 |
| ▸ | ACE | P12821 | 2/20 | 0.43 |
| ▸ | REN | P00797 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 3/20 | 0.41 |
| ▸ | CTSS | P25774 | 3/20 | 0.41 |
| ▸ | CTSK | P43235 | 3/20 | 0.41 |
| ▸ | CTSH | P09668 | 1/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23572623 | 1.00 | CXCL8 (0.48) | CXCL8NAA50BACE1ACEREN | |
| SCHEMBL23572621 | 1.00 | CXCL8 (0.48) | CXCL8NAA50BACE1ACEREN | |
| SCHEMBL16557291 | 0.84 | PPID (0.42) | NAA50 | |
| SCHEMBL30262155 | 0.83 | GRB2 (0.43) | CXCL8CTSLCTSSCTSKCTSH | |
| SCHEMBL23601291 | 0.82 | NMUR2 (0.44) | CXCL8CTSLCTSSCTSKCTSH | |
| SCHEMBL23572612 | 0.82 | NMUR2 (0.44) | CXCL8CTSLCTSSCTSKCTSH | |
| SCHEMBL23572613 | 0.82 | NMUR2 (0.44) | CXCL8CTSLCTSSCTSKCTSH | |
| SCHEMBL23572611 | 0.82 | NMUR2 (0.44) | CXCL8CTSLCTSSCTSKCTSH | |
| SCHEMBL29640706 | 0.81 | NAA50 (0.45) | CXCL8NAA50 | |
| SCHEMBL31497326 | 0.79 | CALCRL (0.46) | CXCL8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11925643-B2 | Toll-like receptor 4 (TLR4) inhibitors and use thereof | MOR RESEARCH APPLICATIONS LTD. (IL) | 2024-03-12 | — | — | US | disclosed |
| US-20210196717-A1 | TOLL-LIKE RECEPTOR 4 (TLR4) INHIBITORS AND USE THEREOF | BAR-ILAN UNIVERSITY (IL) | 2021-07-01 | — | — | US | disclosed |
| US-20210196717-A1 | TOLL-LIKE RECEPTOR 4 (TLR4) INHIBITORS AND USE THEREOF | BAR-ILAN UNIVERSITY (IL) | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11925643-B2 | Toll-like receptor 4 (TLR4) inhibitors and use thereof | TLR4, TLR1, TLR3 | CXCL8 922/4885NAA50 4428/4885BACE1 1619/4885 |
| US-20210196717-A1 | TOLL-LIKE RECEPTOR 4 (TLR4) INHIBITORS AND USE THEREOF | TLR4, TLR1, TLR3 | CXCL8 922/4885NAA50 4428/4885BACE1 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.